https://orcid.org/0000-0002-3360-6899
References
- Rowczenio DM, Noor I, Gillmore JD, et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014;35(9):E2403–E2412.
- Quintas A, Vaz DC, Cardoso I, et al. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem. 2001;276(29):27207–27213.
- Yee AW, Aldeghi M, Blakeley MP, et al. A molecular mechanism for transthyretin amyloidogenesis. Nat Commun. 2019;10(1):925.
- Sebastião MP, Saraiva MJ, Damas AM. The crystal structure of amyloidogenic Leu55 –> pro transthyretin variant reveals a possible pathway for transthyretin polymerization into amyloid fibrils. J Biol Chem. 1998;273(38):24715–24722.
- Redondo C, Damas AM, Olofsson A, et al. Search for intermediate structures in transthyretin fibrillogenesis: soluble tetrameric Tyr78Phe TTR expresses a specific epitope present only in amyloid fibrils. J Mol Biol. 2000;304(3):461–470.
- Magy N, Liepnieks JJ, Gil H, et al. A transthyretin mutation (Tyr78Phe) associated with peripheral neuropathy, carpal tunnel syndrome and skin amyloidosis. Amyloid. 2003;10(1):29–33.
- Reixach N, Deechongkit S, Jiang X, et al. Tissue damage in the amyloidosis: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc. Natl. Acad. Sci. USA. 2004;101(9):2817–2822.
- Episkopou V, Maeda S, Nishiguchi S, et al. Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc Natl Acad Sci USA. 1993;90(6):2375–2379.
- Goldsteins G, Persson H, Andersson K, et al. Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants. Proc Natl Acad Sci USA. 1999;96(6):3108–3113.
- Costa PM, Teixeira A, Saraiva MJ, et al. Immunoassay for transthyretin variants associated with amyloid neuropathy. Scand J Immunol. 1993;38(2):177–182.
- Phay M, Blinder V, Macy S, et al. Transthyretin aggregate-specific antibodies recognize cryptic epitopes on patient-derived amyloid fibrils. Rejuvenation Res. 2014;17(2):97–104.
- Hosoi A, Su Y, Torikai M, et al. Novel antibody for the treatment of transthyretin amyloidosis. J Biol Chem. 2016;291(48):25096–25105.
- Higaki JN, Chakrabartty A, Galant NJ, et al. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin. Amyloid. 2016;23(2):86–97.
- Palha JA, Moreira P, Olofsson A, et al. Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy. J Mol Med. 2001;78(12):703–707.
- Teixeira AC, Saraiva MJ. Presence of N-glycosylated transthyretin in plasma of V30M carriers in familial amyloidotic polyneuropathy: an escape from ERAD. J Cell Mol Med. 2013;17(3):429–435.
- Jiang X, Labaudinière R, et al. A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction. PNAS. 2021;118:1–8.
- Faria TQ, Almeida ZL, Cruz PF, et al. A look into amyloid formation by transthyretin: aggregation pathway and a novel kinetic model. Phys Chem Chem Phys. 2015;17(11):7255–7263.
- Dasari AKR, Hughes RM, Wi S, et al. Transthyretin aggregation pathway toward the formation of distinct cytotoxic oligomers. Sci Rep. 2019;9(1):1–10.